ArticleVirulence2022
Article in Virulence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antifungal resistance and poor clinical outcome rates ofFrontiers in microbiology · 2026Pooled it
- Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study.Open forum infectious diseases · 2025Trial
- Article
- Analysis of the clinical characteristics and nursing strategies for 11 cases of Candida auris bloodstream infection.BMC infectious diseases · 2025Article
- Isolation of Fluconazole-Resistant South Asian Clade Candida auris in Beijing, China.The American journal of tropical medicine and hygiene · 2025Article
- Candida auris cells form giant lipid droplets to survive in harsh environments.Communications biology · 2025Article
- Two outbreaks and sporadic occurrences of Candida auris from one hospital in China: an epidemiological, genomic retrospective study.Infection · 2025Article
- Emergence of multidrug-resistantFrontiers in microbiology · 2025Article
- The rising challenge ofFrontiers in microbiology · 2025Review
- The First Case ofInfection and drug resistance · 2025Article
- Successful Treatment of Bladder Fungus Ball Due toCase reports in pediatrics · 2025Article
- Diosgenin producingComputational and structural biotechnology journal · 2025Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- First report ofEmerging microbes & infections · 2024Article
- Genome-Guided Identification of Surfactin-ProducingInternational journal of molecular sciences · 2024Article
- Sunflower Oil and Cholesterol Nanoemulsion: A Novel Carrier for Micafungin to Combat Multi-ResistantPathogens (Basel, Switzerland) · 2024Article
- The Potential of Dutasteride for Treating Multidrug-ResistantPharmaceutics · 2024Article
- Genome-wide analysis of in vivo-evolved Candida auris reveals multidrug-resistance mechanisms.Mycopathologia · 2024Article
- The role of fungi in the diagnosis of colorectal cancer.Mycology · 2024Review
- Emergence ofSAGE open medical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.